RGLS - Earnings call transcript Q4 2017 | Regulus Therapeutics Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon ladies and gentlemen, and thank you for standing by. Welcome to Regulus Therapeutics Fourth Quarter 2017 Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded.

Now I’d like to welcome and turn the call to Ms. Allison Wey, Vice President of Investor Relations and Corporate Communications.

begin. may You

Allison Wey

Good us Carman. XXXX and you thank results Thank discuss afternoon Regulus' joining to corporate year-end fourth for and you, highlights. everyone quarter financial and

today results and Dan will programs questions. our CEO, line joined We Tim President opening will and before review Chevallard, the Jay on will for Chief Officer Wright, Dan share CFO. and progress are we R&D open Dr. by provide Tim financial remarks, Jay the Hagan, pipeline our

from like remind result prospects, purposes Regulus' the statements Litigation provision Private constitute those with you would and call various XXXX. I contain of Reform certain concerning for this of by Securities Actual which SEC. these filings factors, in as begin, statements will our harbor future of discussed we forward-looking including differ Before the the to safe forward-looking those statements a under performance, corporate that the Act indicated forward-looking important plans, expectations, materially strategy results may

addition, be any In webcast statements. should We any disclaim represent and date. as update only to turn representing call and of Jay. views not the subsequent our date I to upon views of will as this as specifically our call of forward-looking such now the obligations relied any statements over

Jay Hagan

well the active focus as clinical and over all of Thanks changes, amount to and pipeline the the We’ve programs as are of setbacks for transition pre-clinical a applying both two was key tremendous made Allison. added from year learnings XXXX significant year Regulus. We organizational our pipeline. these programs the learned some talents. last had experiences

for changed. the our our of the human the in autosomal WuXi unmet changes biology portfolio all of accomplishments partner programs a Establishing included kidney relationship first therapeutics ahead for protocol areas further treatment complement commercialize ability that to quarter our recent microRNA these our on further significant represent as eventually with and the believe and getting testing RGLSXXXX we as best which team's expand of dominant will you leveraging develop the focus products, ending our strategy the program growing proud the disease We changes and schedule. I'm our in these chance develop of importantly to our give to implemented. study opportunities attractive the amidst in Dan efforts to company manufacture our We with RG-XXX beginning to in with develop heard for has success. milestones and for right financial the investigational year pipeline. the strengthens need. period IND existing relationships that Sanofi medical not we in Importantly, nucleotides from Filing Key our plan. believe line and of the for polycystic expertise accomplishing

Our the and programs for events key portfolio for preclinical and advance toward are XXXX, our milestones, Sanofi advance in data goals XXXX through with option decision clinic. clear, our potential two prepare clinical

enroll underestimated to now. an up our the update had approximately Regarding time studies the with acknowledgement XX the would across We RG-XXX to take by previously that CRO program. today's it we the includes sites together plans two program, the have

We're applied. accelerated from is given has resources number pace than initiations initiation a of through have complexities. longer site However, taking that the anticipated operational halfway and added about we

including than the study data of the end from longer anticipate the study patient we several longer of recruit activities factors due looks a around is QX, this completion HERA and and anticipated achievable to and biopsy While target start enrollment difficult of no to population.

as We we each second are Conservatively in completion we half XXXX studies. these and enrollment more though queue reach the day. to added in key the for patients of investors update of two of dozens have for we milestones. guiding Importantly, being enrollment plan

to development. I program turning that nicely Now Phase progressed early has its through RGLSXXXX,

but a ascending share have half at dose of portion the complete of the or being more Tim to making MAD programs analysis XXXX. In second multi period Meanwhile study. initiation in up anticipate plans about data XXXX of will shortly. the looks summary for follow both of We be others than, and and we a platform are a remains target interest year execution already strong. of novel in frontier about the excited have our advancement. the remain therapeutic of we what as clinical I’m promising partnering we microRNA microRNA class pipeline a which particularly potential beyond demonstrated. microRNA are forefront and

of XX and class. months as target kidney team focused We've two great our to next that talent opportunity demonstrating further within with proof key in the advancing demonstrate of have unique the the proof an important highly programs a management pipeline. added in We together potential therapeutics making progress is concept to mechanism XX microRNA

over more them share And turn to Tim? call plan the as they with update. to about R&D detailed provide to will Tim will We more the move that, I towards clinic.

Tim Wright

Thanks Jay.

the deliver and minimizing Regulus past clinical nuclear Alport to but the Regulus the start have development I’ll my and of to continue that specific knowledge tissues types with preclinical led key capabilities microRNA’s off-target optimal Over our built programs challenges support we to while enhanced and cell advance of types. design other potential to and target with program. effects syndrome we've update relationships year, the to our in internal with R&D CROs therapeutic about

study. Jay of said, expanded initially more the our studies up Alport patients HERA both recruitment speed the that challenging of anticipated, our biopsy was As realizing recruitment we've RG-XXX renal syndrome than to proof efforts concept of and

it resources we'll available estimates results. won't enrolled, have dose of delivery for was drive to whether given a changes and target then and remains and Once back engaged community. orphan able be very same. awareness disease. program patient the this And the our value partnership We drive in any Phase external fully additional biopsy the its topline leadership We to initiation to meeting input this within data to just advised few in forward quarter, determining prior frequency to provide while a also help be their Sanofi engaging. productive in rare and how to weeks We with X provided completed

now to for ADPKD. dominant move our or treatment Let's program the polycystic of disease kidney autosomal RGLSXXXX

I'm chemistry anti-miR-XX about utilizing this This still to While selectively deliver owned designed kidney. proprietary very our early, anti-miR program the wholly our excited program. is the to

we indicated ascending Jay dose escalation. through initiated in and SAD nicely XXXX single December As first this is dose in progressing study or

of study for plans related on early that biomarkers. multiple of making information disease ascending as incorporate on our not have will initiated prior of for X the is but are our since in to we yet XXXX. We Phase still been program too current has way will estimate to RGLSXXXX readout this on dose a the timelines initiation give It’s patients data ADPKD hand the slated initiating study effects now middle the the to gain early

programs on and discovery a well continue efforts immunology. infectious over diseases dozen work the make early liver progress have We to diseases kidney, as and our and half targeting in significant as new on

clinical Dan kidney. these is Stay collaboration over delivery anti-miR months, hold These these of and technologies with tissues for and focused the we’ve of have strategy we approaches, and companies with addition, for profiles. aligned financial delivery. for new turn past advanced our well call liver over technologies promise to being early pipeline of delivery the technologies multiple to are to been research several that target evaluating outside are or performed testing In I’ll now as highly future other exciting the the all in programs. as late novel effort those working pre-clinical This who payloads to for platforms product deliver updates on defined delivery well very Algo tuned optimizing these review. now on efficiently our

Dan Chevallard

Thanks Tim.

we research of exploratory were significant burn and that perspective last resulted be spend that per Coming and impairing of $XX $XX cash year. changes. XXXX mentioned, or one approximately operating nature, a million improvements to our July Jay million areas Regulus was and light per operational would in year reduced in As our organizational for financing guided more transitional of of out changes, that quarter in in

with with cash line and investments. XXXX burn net million that million with Our these the cash, cash projections $XX.X $XX second results operating equivalents approximately were over burn short-term finishing period, cast and year in in the half of

first through expect of We extend nearly cash XXXX. quarter the this to

perspective and RGLSXXXX. RG-XXX As QX from organizational and allocation an financial for the focus both around concentrated ramp activities you were activities expect, our clinical key of up

important Importantly, patients. in were first down of successful study for applied filing associated incremental human Phase partially resources in these for we spend with by were announced syndrome the the wind offset which our initiatives XXXX towards disease IND natural history Cost Alport Athena, and the support of of to initiation study in December. reductions X subsequent

quarter the December same primarily compared million to to development in was XXXX in activities compared was XX, and This completion the a compared decrease $XX.X $X.X resulting per quarter million diluted December of for in period a fourth spaces] the and ended the and stock The and the $XX million million subsequent million our XXXX. $X.X loss XX% a XX% net The down for period net further per G&A G&A results ended loss for fixed net million year in the spend same $XX.X were was million restructuring. decreases XX, Turning comparative year same versus and to $XX.X specifically and May $X.XX $XX.X of in The now programs. and year $X.XX for our year XXXX. XXXX to the XXXX a million result and XXXX. RG-XXX by for the million non-cash $XX XXXX. The $XX.X expenses share for to to period, expenses of XXXX and compared was Net million were quarter to period same and ended primarily share decrease XXXX ended and million the and and the compensation. in for for December research loss period. periods based to respectively and $XX.X for reflects financial XX, related and and quarter $X.XX and million in reduction associated costs [closed a the decrease attributable loss reduction XX, related personnel of were year-over-year quarter $XX.X the $X.XX of basic corporate expenses driven $XX wind December and the

approximately As $XX our of with in we with exit a consistent and rate XXXX we XXXX quarter. guidance, cash in burn million ahead line anticipate per our past look

research will ahead. operating Jay. would two over turn of outlined. Our be back of year it clinical burn pre-clinical the to And our to R&D to efforts exciting XXXX our I that, an We and plan with advancement with approximately Tim programs XX% forward our focused committed to cash like as comprised look pipeline our of

Jay Hagan

presenting be it will thank And conferences be Summing will Tim questions. you very happy as March. up, interest week XXXX week two would for Thanks open Needham is to Cowen the investor year With last today. all is upcoming take execution. for and we please and next your lines? a aside, your Operator, you in it very much important we that,

Operator

[Operator is of Instructions] And our first from Wedbush Liana Moussatos Securities. line from question the

Your line is open.

Liana Moussatos

I the talk liver, it sites kind trials, The and delay for the they the little mean target color? mentioned with up help issues how and for difficult kidney you HERA are enroll that having biopsy starting or to can more can you that you about clinical how sites, it's patients, of - what

Jay Hagan

a to one testing, the year respect more to biopsies, originally but to affects of to operational add, timelines. in don't make I’ll well. site plans the we approximately could development and issues, that mentioned sites audiology number the take end as Tim and the imagine Tim want Liana excuses I as part to or I'll sites so Sure, of amidst that that well our With and program we the again trials any meet as planned you for forth. as don’t want ask first we've that of about know And XX encompasses of the competing that two really then try clinical selection issues confronted population? to trial the I patient to than increased importantly accelerate chime add

Tim Wright

tremendous is recruit sort obviously indication population, add is is to and and through question got to which from this the we're to let about just in the tends Alport need and be recruit interest the community now to and population actually and HERA particular balancing males intended a we’ve Sure, demographic for lot me an to male population of to our how syndrome the patient orphan one a younger is trying interesting the study what trial. what's the commitment the it’s this work support of of younger

last for for is that too we're male of of very them, process these except obviously case, clinical different trial so onerous of settings operational So younger a participate than the side things demographic ability in have a not that's trying part is this this diseases improve usual for but to this subjects while particular the adjustments to rare making participation in population.

Jay Hagan

requires to add these that driving is one of we in with they external clinical or their trials see mean target patients, part what that patient awareness that recall specialized to frequency additional is the to just nothing and that so that's this and alluded I there with nephrologists approved now agents about available Liana new engaged drive which population we're reaching the investigational that resources is outreach that such to two, at for awareness.

Liana Moussatos

on on or that? partnering have any And what of color interest do you comments kind mentioned you areas any

Jay Hagan

been represents published nothing one treating potential has I RG-XXX The years another disease Yes, U.S. the partnered commercial in a approved represents there an mean to attractive are approach last which significant XX very unmet where is Sanofi. obviously already is the over need, and several no novel opportunities. with that well anti-miR

that other in there's there's diseases. and that's pipeline, So manifest in I to opportunity things interest done complex microRNAs potential last growing and of the a creating amongst the to good target think awareness really over year we've partners job our starting and in

Liana Moussatos

Are developing anti-infectious would for something you diseases thinking, those of be in it thinking Or partnerable? was you yourself? immunology mentioned pre-clinical

Jay Hagan

formation a We a our pipeline relative at so as develop for ultimately avenue aspiration, in must significant need for business capabilities want our but terms driving our has to balancing other we fund of would a in we and to ways awareness and also look areas to is in an capital say portfolio. to development program ourselves of there the and I that focusing our job good done yielding it's in efforts fruit interest in unmet Tim do really of pipeline

mentioned and readouts So want add those obviously of to terms things don't were that in faster represent both I for anything. of you opportunities so endpoints if Tim

Tim Wright

we it's building again portfolio that that here out existed where disease say to show proof based the a early has renal partnership which or a to faster whether can the especially clinical branching efficacy biomarkers driving just Yes, several for of strong therefore or was either on concepts mode year. areas ourselves focus in and the in been value last on of into months

Jay Hagan

is as enabling Hepatitis on literature Yes infectious early beyond the to a of and some role a targeting microRNA’s those. growing and there's host programs on additional the further leveraging factor we mature disease validation share that data of on miR-XXX and to are Hep well excited on areas it’s C body those us and of C that lead to

Liana Moussatos

MAD what start for the And to the ADPKD biomarkers and the mentioned up for steps you are trial? study

Jay Hagan

later Yes, stages the finalization. of so actually in we’re

all and regulatory submitting So that have the of to ready place. be it we once components we're get through typical committee going the IRB operational to and review, review we'll starting ethics in once then

volunteer design population our both be pursue a innovative final will that that been biomarkers, and healthy program. into design integrate on our tell plan far ADPKDs but you I MAD we've in early now prepared As more encouraged we regulators patients patients to will those as exploring we've one an by the that the integrate disclosed in will haven't to but importantly it's

Operator

Company. next the from Eric question our Smith line with and comes Cowen And of

Your line is open.

Eric Smith

in biomarker the revised supposed study me XX was be today? of and just the talk exactly you data think when enroll you timelines enrollment that I study that where patients; given It's expect to the from can about little unclear total we a the might to

Jay Hagan

that provides be cohorts up provide for enrollment guess right, we can an when to in dose an and add if of that? any initiation. in anticipated to is protocol to you're when at adjustments look Tim would enrollment and X I see to Phase opportunity the underway XX to complete patients will two appropriate update we frequency so to anything data compare be prior to want you

Tim Wright

numbers is as the we're year. of of give but to second target that is on and the in we're this Jay updates to with recruited underway deliver study making mentioned progress just half going not so specific it Yes, subjects the

Eric Smith

in half the data the second Deliver year. the of

Tim Wright

Yes.

Eric Smith

And timeline. a natural were more I on time that do study there's some publishing specific at a think have you planning point history you

Jay Hagan

Yes, of the analysis office with last is ASN got a medical year there's I underway we together the plan second year and late tons towards. at they're and in the the think work of conference as where half gearing

Operator

with And line our Leerink next Partners. the of question comes Joseph Schwartz from

Your line is open.

Unidentified Analyst

dialing Joe. actually for in [Dagon] is This

to you get the XX are on aspect and have that seen more and sites the that little exactly enrolling in awareness I have you you on you clarification timing did commence that that I when right fruits wanted the So guess have what raising and effort you just you're you hear enrollment currently wise have a seen effort. doing of currently progress,

Jay Hagan

targeting studies. two we So approximately what said was we're the that across XX sites

studies, And And to that ClinicalTrials.gov sites. mid stage can add patients, and in make that conducting you some tackle thus involved drive not when what here also don't other you number sites really stay we up each, research help it’s about the sites breaking put really for number we're actually some are halfway number targeted and clinical sites decide enrollment. of of pace out up far we're a are online moves you through so to both

conducted. underway to patient With And additional so awareness drive tend platforms those that activities and of are to alluded reach theirs at reach and males to where the about includes they target physician, this order need actually younger. population. patient how influence their trial be you they engage, with to ways population, respect given understanding resources, the And see the point respect types media which we that's this being and is different targeted to in are to That tactics frequency social and include are to avenues to Tim that. that other

we and fruits imagine nature tactics the In an that iterative one works of addition and and to more of got them as it's but activities as for detail a we've those of see share underway other to how promising in would can front. techniques you in lot out trying roll happy to that and be seeing

Tim Wright

issues start than way I the where along were place our initiations since sites What additional maybe. some waiting given of us slower in a And these opportunity after the to site of that then instead lot would is all of me see to been some have anticipated, the it has resources add to till put some initiated.

So process as an but Jay early it too future. still we in and said it's iterative it or see see expect it's the to near fruits the very to of

Jay Hagan

One it's ways they've of add with might six target and the you the thing interested and as you patient disease in the got well reach to oftentimes disease out to find as I'll person genetic and one other population information so that here. family leverage who's a the have members

Unidentified Analyst

that $XX do any see Just year. you OpEx anticipated heavily any identification I do were change million remainder for point, that to quarter guess you if require patient the you in that trends per to about branch more the off of invest for you to you to material anticipate even guided would

Jay Hagan

investments that not per budget; we think these manage can significant se. I to are

always know want to that? tactics Dan In don't protective off add I finding opportunities trade for rate. to some resource if allocation you and burn to we're anything meet of terms our additional

Dan Chevallard

additional additional guidance in be savings those burn to we're they think this different the a you being within that as cash I [Dagon] objective think or elsewhere. No, clarify will and confines putting I'd reiterating takes that but, would just today out by don't than I our resources looking to activities into bit expense identifying require them $XX as million for operating provide to mentioned be add yes of is

Operator

Needham question with And line is our from of next and the Company. Alan Carr

Your open. line is

Alan Carr

of continue mostly there A and screen little patient a enrollment. couple trouble the there sounds mentioned Sanofi and them find in up meet [indiscernible] and related do of clause last little that timing of finding sites bit longer the but we'll any getting terms the of all the when ties question U.S. the Sanofi to of to then there to - them actually was if then some when trials like these output here to with a but about you deal patient delays kind over and go challenges It a bit all there proof get these option in to to other way just and or the running its the is concept for that contemplate, data? in this little or when bit

Jay Hagan

ask to amplify on I’ll of those good that Yes, are I missed a in and those few Tim all touch very areas questions.

give last take one will maybe the So the operational first, I’ll piece. then

them as concept and an for our into which XX the XX one with outside provides after patients. Sanofi time for date up to proof period treatment the contract So of study to a completion opportunity through is short a the have, is of of year program opt of weeks year defined one

make provide period we they of time once of option an a that so have to And in sort information, decision. fixed

there's per the on with of that there's passage money included passage that gets in just increased spent the So with of changes no se nothing component. reimbursement time the

we to their a improve given input our weeks long rare get said and appreciate more in their really very drive on diseases. invest, experience a productive awareness we meeting ago ways region couple And as we’d of reimbursed. I and So

are sites they as patients through. typical come of puck and you treated. to operational heard the have screened patients sites study drive type things, one regions need up, up where in side, don't complexity there's from and And where the so have it momentum geographic up really a the in constellation get awareness hockey of as that sort sites and of to patients get you get investigators analogies you key here is you On patients it's you've be can't the where you

seen interested and As how as want detail actually all get in screen targeting our not females learned that of pursuing trial. we far protocol population around we based don’t HERA the there, the we're we you've on from as obviously what often males but the process target And to for going input from is in the they're study ATHENA. get a lot this

investigators of biopsy sort trials any study I initial respect be where interest out are you certain RG-XXX females with directed interested them know letting Tim for in that that and in reaching that number So perspective study. know are to add can to as their there more. to the females of want think participating allowed anything patients to and I

Tim Wright

Jay process and And our as contracting we sites sites up nice of working based just last Those and a identified participation. clip running. and some of IRB the community of sites other up in of is couple delays central and mentioned sites in sites ATHENA at logistics in through study getting with potential have the now the saw academic years a are a process one exclusively were academic running that was we’re almost terms points, a academic that the longer and we've we and for the of that patients than been number is based working just so the for few getting

that's of is the that young terms only progress. the part one So but not of these and of other then regarding in logistics we've screening through the challenges population working operational been process is patient yes, patients the

in far little the that beyond have participate been their were progression patients some So a of too renal disease. to actually terms identified

don't I some that challenges now. the of we trying that do So these right of to where are that think this can face overcome not we the process disease kind in just in of

Operator

the Securities. comes question from of Birchenough next Fargo line our with Jim And Wells

line Your open. is

Unidentified Analyst

program, be now, for from [Nick] you of expect Thanks trials. patients on all the later you this to sending may Jim in multiple is the Alport need on apply Alport enrolling It’s that for be for do any the XXXX could learning dose that afternoon. challenges information there

Jay Hagan

therapies look into just one ability trials the approved of Nick. have of which to there's And ADPKD there population design the patients the year. lot fairly at there larger done feasibility Yes, I'll team take mid the is we're Thanks for willing the seen in of a of question disease their the thus ultimately far an Alport per number already work patient we and study, here U.S. issues you progressive part that. it's the our investigational Phase any next mechanism greater patients, the outside agency precedent wood can planning feasibility we've think demonstrates of to doing so The before se I X as incorporating demonstrating think on couple I a trials we for awareness knock part nature the certainly significantly diagnosed mobilize a are trial incorporating population. don't learnings points, recruit as we're of been proof of anticipate numbers the on And large but that. and X all goal into what are that and of than here the when Phase And of well. after Tim? is first it for the U.S. just that ADPKD

Unidentified Analyst

terms dose, about about dose ascending planning takes lot intend portion? data from you In give it this, do report of data dose is selection, so dose, for lot you’re to single select of of levels, how you to a nine me single months ascending because or this dose a

Jay Hagan

not the in subjects all we’re we're inter-leap database. in the indicated it it is to we study expanded what dose that that relatively have that hand Right, the ensure future, so would lock actually the healthy the complete MAD data driven follow-ups and are before that and the groups, the from doesn’t have an of fact Algo the distant molecule data an is purely we too in hoping is final the duration that want of that actually with number It’s have to timeline we the final And SAD. follow-up we small. adequate start relate from in like to do to by the of planning only fashion to real before

So see any now rate will the but we program, right not of complete that don't part program. limiting. that we in limiting terms it's now is way the rate it as of right in progressing Obviously

Dan Chevallard

in follow-up after with and of the are last that's about mice, in the Yes, in what in required our repeat a dosing we we we’re tissue translates to MAD terms know dose lock hand. efficacy and dosed monkey level in might certain what portion cohort then is dose level the non-human as that’s guiding mouse of have which data to the have achieve so and and we’ve start where several for show seen analyze and exposure efficacy. is where well studies selection where months primate we the model so required we what's exposures question the in the That’s your what of why as see to about we estimation much but in as to the to MAD data, guided achieved, SAD our

Unidentified Analyst

running for middle back have data, HERA, on think going XX-week data HERA? I interim back, a what on to reported plan are to be reporting on and obviously interim by pushed some year, of the you loss Just data now going from is the the that’s XX-week XX-week

Jay Hagan

up in the There endpoint want we're wrapped We but to what break is to hitting the trial not show. the a XX could investors sponsor met that patients to I would obviously interim so analysis. most interim reviewed the blind XX-week data to through and be by powered primary weeks committee guide chance situation analysis the study instructed a the don’t the likely that's that data and is blinded all at analysis, early is the Yes, the continue. monitoring from

So, and we timeline the of be that. XX-week to can that data enrolled then fully some we’ll are reporting we Once provide and those milestones. then analysis data completion upon

Unidentified Analyst

patient So XX sort the last would weeks be on from in? of interim based the

Jay Hagan

That’s right, correct.

Operator

question next from [Operator BMO the our Luchini Matthew Instructions] Capital. line of from And is

line is open. Your

Matthew Luchini

please. me from couple So

the secondly in on half through a Is you about I accelerate little dose multi-ascending of and then XX how should general specific site through of identifying that ascending they as to than of so next along additional guys hear of to then trial the or the be correct provided and was first finally sort now XX. sites results bring guidance mid-year couple did the mentioned at Sanofi could the you that XXXX, mentioned later Alport Thanks. stick XX trial closer what program, if to to active looking discussed helping to move to the year? sites and you or the has of give already couple terms adding number the total And of we recruitment. a sites times times for So that have activation. about way plan data a XX sense you’re And -- from you've hasn't should just those guidance sites with halfway the about sites suggested single or guess from Maybe us no before you it far. maybe you that communicate I and expected expect been just portion portion it dose

Tim Wright

through when you trial, to alluded they up, Yes, adding add move you I to based clinical on patients. any going especially change to sites evaluating sites put are additional you don't them appear opportunity down, mid-phase earlier so getting traction for process the on might constantly be shut

feel patients like we recruitment. evaluating additional sites are we adding we So with get traction where might and

how that to of as so portion that's MAD plan of the is respect So year MAD Tim have the up portion complete we results, you’re Phase in influx. mechanism I'll to, expect will results of mix, we’d one XXXX, and the and next we single mid those our communicated report wrap the those portion trial topline study to, how communication, from in it obviously by time. that guided with the correct current take initiate results the X proof should the that and is just once respect the to last ascending all dose all With

Jay Hagan

ways to of those driving a and the And we’re anecdotes engagement through types steering outreach so investigators drive the with foundations, awareness of and into to either history and more can sense through committee amongst Tim about regional different ways they this that long and they've have a rare sharing in provided share the among diseases with cooperative obviously guidance of things the efforts. employing evaluating but joint our tactics all Sanofi respect seen physicians, has to and

Tim Wright

at trial has very over it's of last as an gotten we've think ongoing months least this especially couple and dialogue I up been the running. Yes last and over been years well helpful several the the

and us. to helpful anecdotes has and formal for togethers in reviewing the having program new between the very face continue certainly our said to get Jay but sharing identify We and face recruit as been to population dialogue ways hard

Operator

our final today. for call Mr. the to Thank his you. that will And Jay ends turn session for to I Q&A Hagan like back remarks.

Jay Hagan

Thanks very move programs much and for look these your attention today Thank you. we time as and forward providing to forward. updates

Operator

you that a disconnect. may in and program the ladies conference. gentlemen concludes with And today's participating you Have all wonderful and thank This for day. we

Regulus Therapeutics (RGLS) 7 Mar 182017 Q4 Earnings call transcript